Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

DURANCE DURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr
Local Project Reference:	121881
Principal Investigator:	Dr. Mark Linch
Drug Class/ Treatment:	Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine)
Patient Population:	Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ABACUS-2 ABACUS-2: Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
Local Project Reference:	135538
Principal Investigator:	Dr. Mark Linch
Drug Class/ Treatment:	Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:	Patient requiring surgery with: Cohort 1: T1 high grade - T4a of the bladder with mixed (dominant) or rare histological subtype Cohort 2: Upper urinary tract (high grade or high risk)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

EPIC EPIC Trial: A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma
Local Project Reference:	126549
Principal Investigator:	Dr. Constantine Alifrangis
Drug Class/ Treatment:	Cemiplimab (Humanised Monoclonal IgG4 Antibody Targeting PD-1/PD-L1 Pathway) Monotherapy or Combination with SOC Chemotherapy
Patient Population:	Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

TRIALS on-Hold to recruitment

POTENTIA (CBT307-1) A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA)
Local Project Reference:	129679
Principal Investigator:	Dr. Anuradha Jayaram
Drug Class/ Treatment:	CB307 (Trispecific Humabody T-Cell Enhancer)
Patient Population:	PSMA+ (IHC) Advanced or Metastatic Solid Tumours

Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

DURANCE

ABACUS-2

EPIC

TRIALS on-Hold to recruitment

POTENTIA (CBT307-1)

Principal Investigator(s):

Dr. mark linch

Dr. Anuradha Jayaram